Skip to main content
. Author manuscript; available in PMC: 2013 Feb 17.
Published in final edited form as: ACS Chem Biol. 2011 Nov 17;7(2):367–377. doi: 10.1021/cb2004274

Figure 7. Pharmacokinetic (PK) analysis of compound 1.

Figure 7

(a) Hepatic microsomal stability of compound 1. The half-life (t1/2) of the inhibitor was calculated from its decrease with time, using linear regression. (b) Serum concentration of compound 1 in mice injected (i.p.) with compound 1 at 3 mg/kg; blood serum was collected after 5, 20, 60, and 120 min.

HHS Vulnerability Disclosure